Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | EVP & GENERAL COUNSEL | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,172 |
Ending reported balance
After 2026-10-01 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 8,300 · Balance 53,472 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Row 2 · 2026-10-01 · Sale · Disposed 880 · Balance 52,592 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-10-01 · Sale · Disposed 1,480 · Balance 51,112 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-10-01 · Sale · Disposed 780 · Balance 50,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-10-01 · Sale · Disposed 1,480 · Balance 48,852 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-10-01 · Sale · Disposed 400 · Balance 48,452 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-10-01 · Sale · Disposed 720 · Balance 47,732 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-10-01 · Sale · Disposed 739 · Balance 46,993 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-10-01 · Sale · Disposed 838 · Balance 46,155 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 10 · 2026-10-01 · Sale · Disposed 823 · Balance 45,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2026-10-01 · Sale · Disposed 160 · Balance 45,172 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 39,240 |
Reported balance
After 2026-10-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-01 · Exercise / conversion · Disposed 8,300 · Balance 39,240 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2022 Filed Jul 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007576 · form4-07082022_040701.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $243.67 | $170,572.01 |
DisclosureSEC source: 0001415889-22-007576 · form4-07082022_040701.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $243.60 to $243.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,600 | $242.80 | $631,287.80 |
DisclosureSEC source: 0001415889-22-007576 · form4-07082022_040701.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,097 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $242.365 to $243.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 800 | $241.89 | $193,508.48 |
DisclosureSEC source: 0001415889-22-007576 · form4-07082022_040701.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,697 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $241.245 to $242.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,900 | $240.46 | $456,869.06 |
DisclosureSEC source: 0001415889-22-007576 · form4-07082022_040701.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,497 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $240.01 to $240.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-007576 · form4-07082022_040701.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006748 · form4-06172022_040608.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $216.47 | $21,647.00 |
DisclosureSEC source: 0001415889-22-006748 · form4-06172022_040608.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,484 | $215.93 | $752,302.56 |
DisclosureSEC source: 0001415889-22-006748 · form4-06172022_040608.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,497 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $215.45 to $216.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,416 | $215.03 | $519,522.39 |
DisclosureSEC source: 0001415889-22-006748 · form4-06172022_040608.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,981 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $214.39 to $215.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-006748 · form4-06172022_040608.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006116 · form4-06032022_040606.xml · derivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $228.11 | $45,621.00 |
DisclosureSEC source: 0001415889-22-006116 · form4-06032022_040606.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 600 | $226.82 | $136,093.02 |
DisclosureSEC source: 0001415889-22-006116 · form4-06032022_040606.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,597 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $226.44 to $227.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 161 | $224.81 | $36,194.23 |
DisclosureSEC source: 0001415889-22-006116 · form4-06032022_040606.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,197 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $224.39 to $225.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,202 | $223.72 | $492,629.02 |
DisclosureSEC source: 0001415889-22-006116 · form4-06032022_040606.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,358 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $223.37 to $224.215. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,837 | $222.98 | $632,585.75 |
DisclosureSEC source: 0001415889-22-006116 · form4-06032022_040606.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,560 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.32 to $223.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-006116 · form4-06032022_040606.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005403 · form4-05202022_040513.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · derivative.exercise_date: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 800 | $185.19 | $148,155.04 |
DisclosureSEC source: 0001415889-22-005403 · form4-05202022_040513.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $184.90 to $185.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $184.10 | $92,052.00 |
DisclosureSEC source: 0001415889-22-005403 · form4-05202022_040513.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,197 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $183.88 to $184.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,700 | $183.06 | $860,385.76 |
DisclosureSEC source: 0001415889-22-005403 · form4-05202022_040513.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,697 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $182.60 to $183.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-005403 · form4-05202022_040513.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| May 05, 2022 Filed May 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004708 · form4-05062022_040507.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F6 · derivative.exercise_date: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. Read SEC document |
| May 05, 2022 Filed May 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $192.92 | $135,045.47 |
DisclosureSEC source: 0001415889-22-004708 · form4-05062022_040507.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $192.50 to $193.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2022 Filed May 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 900 | $191.72 | $172,550.97 |
DisclosureSEC source: 0001415889-22-004708 · form4-05062022_040507.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,097 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $191.315 to $191.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2022 Filed May 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,100 | $190.36 | $590,107.63 |
DisclosureSEC source: 0001415889-22-004708 · form4-05062022_040507.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,997 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $190.085 to $190.955. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2022 Filed May 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,300 | $189.38 | $246,189.45 |
DisclosureSEC source: 0001415889-22-004708 · form4-05062022_040507.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,097 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $188.955 to $189.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2022 Filed May 6, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-004708 · form4-05062022_040507.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| April 21, 2022 Filed Apr 22, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004230 · form4-04222022_040407.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · derivative.exercise_date: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. Read SEC document |
| April 21, 2022 Filed Apr 22, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,801 | $189.66 | $720,905.64 |
DisclosureSEC source: 0001415889-22-004230 · form4-04222022_040407.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $189.25 to $190.125. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 21, 2022 Filed Apr 22, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,599 | $188.77 | $301,850.11 |
DisclosureSEC source: 0001415889-22-004230 · form4-04222022_040407.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,288 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $188.24 to $189.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 21, 2022 Filed Apr 22, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 600 | $187.20 | $112,321.98 |
DisclosureSEC source: 0001415889-22-004230 · form4-04222022_040407.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,887 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $186.855 to $187.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 21, 2022 Filed Apr 22, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-004230 · form4-04222022_040407.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003958 · form4-04082022_040401.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · derivative.exercise_date: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,200 | $186.50 | $223,794.00 |
DisclosureSEC source: 0001415889-22-003958 · form4-04082022_040401.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,487 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $186.40 to $186.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,886 | $185.79 | $350,406.35 |
DisclosureSEC source: 0001415889-22-003958 · form4-04082022_040401.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,687 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $185.33 to $186.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,914 | $184.93 | $538,894.18 |
DisclosureSEC source: 0001415889-22-003958 · form4-04082022_040401.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,573 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $184.31 to $185.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-003958 · form4-04082022_040401.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003188 · form4-03182022_040336.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F7 · derivative.exercise_date: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 350 | $184.15 | $64,454.01 |
DisclosureSEC source: 0001415889-22-003188 · form4-03182022_040336.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,487 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F6 · price: This transaction was executed in multiple trades at prices ranging from $183.99 to $184.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,281 | $183.25 | $234,746.32 |
DisclosureSEC source: 0001415889-22-003188 · form4-03182022_040336.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,837 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $182.75 to $183.6375. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,865 | $182.14 | $703,986.17 |
DisclosureSEC source: 0001415889-22-003188 · form4-03182022_040336.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,118 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $181.62 to $182.505. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 504 | $181.18 | $91,314.72 |
DisclosureSEC source: 0001415889-22-003188 · form4-03182022_040336.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,983 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $180.56 to $181.465. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-003188 · form4-03182022_040336.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · balance_after: Includes 118 shares acquired on March 4, 2022, under the United Therapeutics Corporation Employee Stock Purchase Plan. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002548 · form4-03042022_010313.xml · derivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · derivative.exercise_date: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021 Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $174.70 | $69,878.48 |
DisclosureSEC source: 0001415889-22-002548 · form4-03042022_010313.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,369 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $174.59 to $174.895. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5,600 | $174.08 | $974,836.24 |
DisclosureSEC source: 0001415889-22-002548 · form4-03042022_010313.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,769 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $173.58 to $174.455. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $111.00 | $666,000.00 |
DisclosureSEC source: 0001415889-22-002548 · form4-03042022_010313.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001567 · form4-02182022_040204.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,552 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.